Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Caitlin L. Costello; Tara K. Gregory; Syed Abbas Ali; Jesus G. Berdeja; Krina K. Patel; Nina D. Shah; Eric Ostertag; Chris Martin; Majid Ghoddusi; Devon J Shedlock; Matthew A. Spear; Robert Z. Orlowski; Adam D. Cohen

doi:10.1182/BLOOD-2019-129562

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Caitlin L. Costello
, Tara K. Gregory
, Syed Abbas Ali
, Jesus G. Berdeja
, Krina K. Patel
, Nina D. Shah
, Eric Ostertag
, Chris Martin
, Majid Ghoddusi
, Devon J Shedlock
, Matthew A. Spear
, Robert Z. Orlowski
, Adam D. Cohen

University of California, San Diego
Sarah Cannon Research Institute
Sidney Kimmel Comprehensive Cancer Center, John's Hopkins Hospital, Baltimore, MD
Sarah Cannon Center For Blood Cancers, Nashville, TN
University of Texas MD Anderson Cancer Center
University of California, San Francisco
Poseida Therapeutics, Inc., San Diego, CA
Poseida Therapeutics, San Diego, CA
University of Pennsylvania

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	134
DOIs	https://doi.org/10.1182/BLOOD-2019-129562
State	Published - Nov 13 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1182/BLOOD-2019-129562License: Unspecified

Cite this

Costello, C. L., Gregory, T. K., Ali, S. A., Berdeja, J. G., Patel, K. K., Shah, N. D., Ostertag, E., Martin, C., Ghoddusi, M., Shedlock, D. J., Spear, M. A., Orlowski, R. Z., & Cohen, A. D. (2019). Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME). Blood, 134. https://doi.org/10.1182/BLOOD-2019-129562

@article{75c2b08a49f9426387e6d195d14b1f8d,

title = "Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)",

author = "Costello, \{Caitlin L.\} and Gregory, \{Tara K.\} and Ali, \{Syed Abbas\} and Berdeja, \{Jesus G.\} and Patel, \{Krina K.\} and Shah, \{Nina D.\} and Eric Ostertag and Chris Martin and Majid Ghoddusi and Shedlock, \{Devon J\} and Spear, \{Matthew A.\} and Orlowski, \{Robert Z.\} and Cohen, \{Adam D.\}",

note = "Caitlin L. Costello, Tara K. Gregory, Syed Abbas Ali, Jesus G. Berdeja, Krina K. Patel, Nina D. Shah, Eric Ostertag, Chris Martin, Majid Ghoddusi, Devon J Shedlock, Matthew A. Spear, Robert Z. Orlowski, Adam D. Cohen; Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME).",

year = "2019",

month = nov,

day = "13",

doi = "10.1182/BLOOD-2019-129562",

language = "American English",

volume = "134",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

AU - Costello, Caitlin L.

AU - Gregory, Tara K.

AU - Ali, Syed Abbas

AU - Berdeja, Jesus G.

AU - Patel, Krina K.

AU - Shah, Nina D.

AU - Ostertag, Eric

AU - Martin, Chris

AU - Ghoddusi, Majid

AU - Shedlock, Devon J

AU - Spear, Matthew A.

AU - Orlowski, Robert Z.

AU - Cohen, Adam D.

N1 - Caitlin L. Costello, Tara K. Gregory, Syed Abbas Ali, Jesus G. Berdeja, Krina K. Patel, Nina D. Shah, Eric Ostertag, Chris Martin, Majid Ghoddusi, Devon J Shedlock, Matthew A. Spear, Robert Z. Orlowski, Adam D. Cohen; Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME).

PY - 2019/11/13

Y1 - 2019/11/13

UR - https://ashpublications.org/blood/article/134/Supplement_1/3184/423869/Phase-2-Study-of-the-Response-and-Safety-of-P-Bcma

U2 - 10.1182/BLOOD-2019-129562

DO - 10.1182/BLOOD-2019-129562

M3 - Article

VL - 134

JO - Blood

JF - Blood

ER -

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Disciplines

Access to Document

Other files and links

Cite this